Metrics Behind the Money: The Health Economic Playbook for Builders and Backers
Moderator
Melanie D Whittington, MS, PhD, Leerink Center for Pharmacoeconomics, Boston, MA, United States
Speakers
Meng Li, MS, PhD, Tufts Medical Center; Stifel, Boston, MA, United States; Richard Xie, PhD, RA Capital Management, Newton, MA, United States; Sorochi Van Sickle, PhD, Patient Square Capital, Menlo Park, CA, United States; Nadine Zawadzki, PhD, MPH, FTI Consulting, Los Angeles, CA, United States; Jason Shafrin, PhD, FTI Consulting, Los Angeles, CA, United States
In an era of constrained capital, early-stage biotech investors win by seeing what others miss — and HEOR is rapidly becoming the new analytical edge that separates disciplined conviction from costly optimism. This session unifies the science-first diligence mindset with the quantitative “metrics behind the money” that top funds now use to evaluate risk, commercial potential, and eventual payer acceptance. Investors will learn how HEOR-driven signals sharpen early assessments of unmet need, differentiation, pricing, and value inflection, while also revealing the evidence gaps that stall IC approvals or slow capital deployment. The result is a practical, high-velocity framework for picking winners in the pre-clinical landscape — grounded in the metrics that actually move investment decisions.
Topic
Organizational Practices